The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
A new Optum Rx report identifies three drugs targeting chronic conditions that are under review by the FDA. The medications address significant cost drivers for payers, including weight management and chronic inflammatory conditions.
Research suggests a daily GLP-1 pill could be a promising option for weight management. The results indicate a potential alternative to injectable weight loss treatments. Health tracking apps like Shotlee can help monitor progress.
Analyses of GLP-1 receptor agonists for weight management show clinically significant weight loss compared to placebo. However, long-term safety and potential side effects remain uncertain. Financial ties influencing study results are also a concern.
It's common to gain weight in winter due to cold weather, festive treats, and less activity. However, you can manage your weight by staying active, eating healthy, and addressing common causes. Here's how to avoid winter weight gain.
WeightWatchers intends to offer Novo Nordisk's oral Wegovy upon potential FDA approval. This strategic move occurs amidst a competitive weight-loss drug market, aiming to provide a convenient alternative to injections. The FDA is also expediting GLP-1 treatments to improve access.
Hair loss, or 'GLP-1 shedding,' can be a concerning side effect for those using GLP-1 drugs. However, solutions are available to effectively address this issue. A dermatologist provides insights into managing hair loss associated with these medications.
Meghan Trainor's slimmer appearance, attributed to Mounjaro, has ignited online discussions. While some celebrate her health dedication, others miss her earlier look. The debate highlights body image and societal pressures.
Research indicates that GLP-1 therapies offer enhanced weight benefits compared to metformin in adolescents diagnosed with type 2 diabetes. The study highlights comparable glycemic control with GLP-1 drugs but superior weight reduction.
New research indicates that semaglutide and tirzepatide, drugs used for managing type 2 diabetes, exhibit heart-protective effects in real-world settings, mirroring findings from clinical trials. The study highlights the cardiovascular benefits these medications offer to patients in everyday clinical practice.
